Company intelligence / Profile preview

Phanes Biotech

Malvern, Pennsylvania, United Statesphanesbiotech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Phanes Biotech has developed two lead programs for Alzheimer’s disease and related neurodegenerative disorders. PB021, a peptidergic small molecule, has shown preclinical efficacy in preventing neuronal destruction and promoting neuroregeneration. PB43D, a monoclonal antibody targeting tau pathology, also reduces amyloid beta pathology. The company aims to initiate Phase I/II clinical trials in AD patients. No published human clinical results as of June 2025.

Therapeutic areas: Neurology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

P021

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Veravas (strategic partnership for development/licensing)

Beyond the preview

Go deeper on Phanes Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phanes Biotech.

Explore the full profile